American Oncology Network (NASDAQ:AONC) and partner practice Florida Oncology and Hematology announced the addition of Board-certified medical oncologist and hematologist Dr. Vitor Pastorini to the physician team in Fort Myers and Cape Coral.
FOH now has nine medical oncologists and 15 advanced practice providers across five Florida locations.
Loading...
Loading translation...
Positive
None.
Negative
None.
News Market Reaction – AONC
-99.17%
-99.17%Session close to close
In the Jun 9 session, AONC declined 99.17%, reflecting a significant negative market reaction.
The stock dropped -99.2% in the session following this news. A negative reaction despite an apparent...
Analysis
The stock dropped -99.2% in the session following this news. A negative reaction despite an apparently constructive staffing update would fit a pattern where some expansion news, such as the Oncology Consultants transaction that saw a -7.33% move, met with investor skepticism. Market participants may at times focus on integration, execution, or capital-allocation questions rather than headline growth. Mixed historical responses to similar network-building announcements suggest that reactions have not been uniformly positive.
Key Figures
Experience in Florida:10 yearsMedical oncologists at FOH:9 physiciansAdvanced practice providers:15 providers+5 more
8 metrics
Experience in Florida10 yearsDr. Pastorini’s clinical practice in Florida
Medical oncologists at FOH9 physiciansFOH team size after Dr. Pastorini joins
Advanced practice providers15 providersFOH advanced practice team across locations
Florida locations5 locationsFOH sites across Florida
Clinical trials access500+ trialsZangmeister Cancer Center affiliation with OSUCCC–James
Oncology Consultants locations18 locationsOncology Consultants footprint in South Texas
Oncology Consultants oncologists16 medical oncologistsOncology Consultants staff mix
RKV Medical Center becomes AON’s first Oklahoma partner practice.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
Recent partnership and expansion news has generally seen positive or flat reactions, with one notable selloff on a practice-joining announcement.
Recent Company History
Over the past few months, AONC has repeatedly highlighted network expansion and thought-leadership. In Feb 2026, RKV Medical Center joined as the first Oklahoma partner. In Mar 2026, Oncology Consultants with 18 locations and 16 medical oncologists joined. April brought a new physician at MidAmerica Cancer Care and presentation plans for 11 sessions at a major conference. In May 2026, Zangmeister Cancer Center affiliated with OSUCCC–James, adding access to over 500 clinical trials.
Key Terms
hematology, oncology, board-certified, clinical trials, +4 more
8 terms
hematologymedical
"Board-certified medical oncologist and hematologist Vitor Pastorini, MD"
Hematology is the branch of medicine that studies blood, its components (like red and white cells and platelets), and disorders that affect them. For investors, it matters because treatments, diagnostics, and devices that diagnose or fix blood problems can drive sales, regulatory risk, and patent value—think of it as investments in the maintenance and repair of the body's delivery system, where breakthroughs or setbacks can quickly change a company's prospects.
oncologymedical
"Community oncology practice Florida Oncology and Hematology (FOH)"
Oncology is the branch of medicine focused on understanding, diagnosing, and treating cancer, including the development and testing of drugs, therapies, and screening methods. It matters to investors because advances, trial results, regulatory approvals, or setbacks in cancer research can dramatically change the value of companies and the size of potential markets—think of oncology news as weather reports that help investors steer financial decisions in a high-stakes field.
board-certifiedmedical
"Board-certified medical oncologist and hematologist Vitor Pastorini, MD"
Board-certified describes a professional—most often a physician or other clinical specialist—who has completed required specialty training and passed standardized exams administered by a recognized certifying board. For investors, board certification is a quick signal of verified expertise and credibility in critical roles such as clinical development, regulatory strategy, or medical advisory positions, and can reduce perceived execution and regulatory risk much like a credentialed mechanic reassures a buyer about a car’s condition.
clinical trialsmedical
"services for diagnosis, treatment, clinical trials, survivorship, and patient support"
Clinical trials are carefully controlled studies that test whether a new drug, device or treatment is safe and effective in people, moving through successive stages that increase the number of participants and the rigor of testing. Investors care because trial outcomes determine whether a product can be approved and sold, shaping a company’s future revenue, valuation and risk profile—think of it as proof-of-concept testing that decides if a prototype becomes a market-ready product.
advanced practice providerstechnical
"now includes nine medical oncologists and 15 advanced practice providers"
Advanced practice providers are licensed healthcare professionals—such as nurse practitioners and physician assistants—who perform many of the same patient-care tasks as physicians, including diagnosing, prescribing, and managing treatment. Think of them as experienced deputies who increase a practice’s capacity and efficiency; for investors, their use can lower staffing costs, speed patient access, and influence revenue and profit margins depending on licensing rules and reimbursement rates.
car t-cell therapymedical
"expertise, CAR T-cell therapy, stem cell transplant evaluation"
Car T-cell therapy is a medical treatment that uses a patient’s own immune cells, modified in a lab to better recognize and attack cancer cells. It is considered a breakthrough because it offers potentially long-lasting effects for certain types of cancer. For investors, its development and approval can signal advances in healthcare innovation and potential growth opportunities in the biotech sector.
"tumor-infiltrating lymphocyte (TIL) therapy and proton therapy at OSUCCC"
Tumor-infiltrating lymphocyte (TIL) therapy is a type of immunotherapy that harvests a patient’s own immune cells found inside a tumor, grows and activates them in the lab, then returns them to the patient to help fight cancer. Think of it as boosting and retraining a patient’s local tumor-fighting cells like tuning and amplifying a home security system. Investors watch TIL therapy because clinical trial results, manufacturing complexity, and regulatory approval determine its commercial potential and company value.
proton therapymedical
"tumor-infiltrating lymphocyte (TIL) therapy and proton therapy at OSUCCC"
A cancer treatment that uses a beam of charged particles (protons) to deliver radiation precisely to a tumor while limiting damage to surrounding healthy tissue; think of it as a GPS-guided beam that stops where the tumor is instead of blasting through everything. It matters to investors because proton therapy requires very expensive equipment, long-term facility investment and depends on clinical outcomes and insurance reimbursement to generate revenue, so advances in effectiveness, cost or access can materially affect providers' financial prospects.
FORT MYERS, Fla., June 09, 2026 (GLOBE NEWSWIRE) -- Community oncology practice Florida Oncology and Hematology (FOH), a partner practice of American Oncology Network (AON), is pleased to welcome Board-certified medical oncologist and hematologist Vitor Pastorini, MD, to its physician care team. Dr. Pastorini is now accepting patients at the Fort Myers and Cape Coral practices.
Dr. Pastorini is Board-certified by the American Board of Internal Medicine and has been serving patients in Florida for 10 years. He earned his medical degree from the Universidade Federal da Bahia in Brazil and completed his internship and residency in internal medicine at the University of Miami/Jackson Memorial Hospital, where he served as Chief Medical Resident. He went on to complete a fellowship in hematology and oncology at the University of Pittsburgh Medical Center.
“I am eager to join the physician team at Florida Oncology and Hematology,” said Dr. Pastorini. “FOH provides exceptional, patient-centered care that aligns with my personal patient care goals. I look forward to working alongside the team in providing innovative, comprehensive care to our community.”
The Florida Oncology and Hematology team now includes nine medical oncologists and 15 advanced practice providers across five Florida locations. The practice is committed to providing the community with innovative cancer care that is delivered holistically based on research and evidence-based medicine. FOH cancer patients have access to a diverse range of services for diagnosis, treatment, clinical trials, survivorship, and patient support that are close to home, eliminating the need to travel long distances to receive care.
“We are thrilled to welcome Dr. Pastorini to Florida Oncology and Hematology,” said Venkata Parsa, MD, medical oncologist and hematologist at FOH. “His impressive education and experience make him an excellent member of our team. His commitment to delivering innovative, evidence-based care will further enhance our ability to deliver an exceptional patient experience.”
“On behalf of AON, I am pleased to welcome Dr. Pastorini to Florida Oncology and Hematology, and the network,” said Stephen “Fred” Divers, MD, AON’s chief medical officer. “Dr. Pastorini’s extensive background makes him a great addition to the team, and I am confident that our patients will benefit from his commitment to providing quality, patient-centered care.”
For more information about AON, visit AONcology.com. For more information about Florida Oncology and Hematology visit floridaonc.com.
About American Oncology Network American Oncology Network (AON) is an alliance of physicians and seasoned healthcare leaders partnering to ensure the long-term success and viability of community oncology and other specialties. Founded in 2018, AON’s rapidly expanding network represents more than 350 providers practicing across 21 states. AON pioneers innovative healthcare solutions through its physician-led model, fostering value-based care that improves patient outcomes while reducing costs and expanding access to quality care. AON equips its network physicians with the tools they need to thrive independently while providing comprehensive support, integrated revenue-diversifying ancillary services, and practice management expertise, enabling physicians to focus on what matters most – providing the highest standard of care for every patient. AON is committed to promoting health equity by addressing disparities in cancer care and ensuring that all patients have access to the care they need to achieve optimal health outcomes. With a focus on innovation and collaboration, AON is shaping the future of community oncology. For more information, please visit AONcology.com or follow us on LinkedIn, Facebook, X (formerly Twitter) and YouTube.
About Florida Oncology and Hematology Specialists in the diagnosis and treatment of cancer and blood disorders, Florida Oncology and Hematology serves patients in Cape Coral, Clearwater, Fort Myers, and Naples, Florida. As a community-based practice, Florida Oncology and Hematology offers a full range of exceptional cancer services, providing the highest quality treatments based on research and focused on the whole person. Learn more at floridaonc.com.
Media Contact:
Karen Riley Sawyer
American Oncology Network
Karen.Sawyer@AONcology.com
FAQ
Who is Dr. Vitor Pastorini joining Florida Oncology and Hematology under American Oncology Network (AONC)?
Dr. Vitor Pastorini is a Board-certified medical oncologist and hematologist joining Florida Oncology and Hematology. According to American Oncology Network, he has 10 years of experience treating Florida patients and completed fellowship training in hematology and oncology at the University of Pittsburgh Medical Center.
What locations will Dr. Vitor Pastorini serve for Florida Oncology and Hematology under AONC?
Dr. Vitor Pastorini will see patients at Florida Oncology and Hematology’s Fort Myers and Cape Coral locations. According to American Oncology Network, these community practices offer diagnosis, treatment, clinical trials, survivorship, and support services so patients can receive advanced cancer care close to home.
How does Dr. Vitor Pastorini’s arrival change the Florida Oncology and Hematology team size?
With Dr. Pastorini joining, Florida Oncology and Hematology now includes nine medical oncologists and 15 advanced practice providers. According to American Oncology Network, these clinicians work across five Florida locations to deliver innovative, evidence-based, patient-centered cancer care within the community setting.
What is Dr. Vitor Pastorini’s medical training before joining American Oncology Network partner FOH?
Dr. Pastorini earned his medical degree in Brazil and trained in the United States. According to American Oncology Network, he completed internal medicine residency and Chief Medical Resident service at University of Miami/Jackson Memorial Hospital, then a hematology and oncology fellowship at University of Pittsburgh Medical Center.
What type of cancer care does Florida Oncology and Hematology provide as part of American Oncology Network (AONC)?
Florida Oncology and Hematology focuses on innovative, research-based community cancer care. According to American Oncology Network, FOH offers services for diagnosis, treatment, access to clinical trials, survivorship, and broad patient support, helping patients avoid long-distance travel for comprehensive oncology and hematology care.
